The Institute for Clinical and Economic Review in a new report suggests that Janssen’s Xarelto and Amarin Pharma’s Vascepa both are cost-effective additive cardiovascular disease therapies.
According to a press release, the report will be reviewed during the upcoming Sept. 26 meeting of the Midwest Comparative Effectiveness Public Advisory Council in St. Louis, Missouri.
“Cardiovascular disease is the leading cause of death in the United States,” ICER CMO David Rind said in a statement. “Tremendous health gains have been achieved with now inexpensive treatments such as aspirin and statins, but high-risk patients have substantial rates of cardiovascular events even on these treatments. Our evidence review suggests that treatments like rivaroxaban and icosapent ethyl can provide additional benefits for such patients, and have prices that reflect those benefits.”
To read the evidence report on ICER’s website, click here.